Group 1: Market Overview - The Hang Seng Index fell by 0.66%, down 165 points, closing at 25,035 points, while the Hang Seng Tech Index decreased by 1.04% [1] - Early trading volume in Hong Kong stocks reached HKD 210.8 billion [1] Group 2: Chip Industry Insights - According to TrendForce, the proportion of external chip suppliers in China's AI server market is expected to drop from 63% in 2024 to 42% by 2025, while local chip suppliers' share may rise to 40%, indicating a trend towards domestic substitution [1] - Chip stocks saw gains, with Shanghai Fudan up 5.79%, SMIC up 8.27%, and Huahong Semiconductor up 4.64% [1] Group 3: Company Performance Highlights - China Cinda's stock rose by 9.74% after reporting a 5.8% year-on-year increase in net profit for the first half of the year, reinforcing its advantage in the non-performing asset management sector [2] - Yadea Holdings' stock increased by over 5% as its net profit for the first half of the year surged nearly 60%, with the new national standard expected to usher in a new industry cycle [3] - CNOOC's stock rose by 4.4% following a mid-term net profit of approximately CNY 69.5 billion, with further potential in overseas exploration [4] - Television Broadcasts' stock fell over 9%, reporting a loss of HKD 108 million for the first half of the year, but expects to achieve positive net profit for the year [5] - Alibaba's stock declined by 3.74% ahead of its first fiscal quarter earnings report, with market concerns regarding the impact of flash sale investments on profits [6] - Lao Pu Gold's stock dropped nearly 4% due to a reduction in shares by the company's incentive platform, although the controlling shareholder did not sell any shares [7] - Smoore International's stock fell over 8%, with a nearly 28% year-on-year decrease in net profit for the first half of the year, affected by increased R&D expenditures [8]

Group 1: Automotive Industry Insights - The automotive industry is experiencing a significant shift towards intelligent driving technologies, with companies like HUAWEI and Horizon leading the way in advanced driver assistance systems [13][14]. - The penetration rate of L2 and above autonomous driving features in passenger vehicles reached 29.7% as of June 2025, reflecting a year-on-year increase of 13 percentage points [14]. - Investment recommendations include companies such as Xpeng Motors, Leap Motor, and Geely for complete vehicles, and suppliers like Suoteng Technology and Hesai Technology for components [15]. Group 2: Pharmaceutical Sector Developments - The pharmaceutical sector showed weaker performance compared to the overall market, with the biopharmaceutical segment rising only 1.05% [16]. - The World Lung Cancer Conference (WCLC) in September 2025 will showcase innovative research from Chinese pharmaceutical companies, highlighting the growing competitiveness of domestic products [16][17]. - Investment focus is recommended on companies presenting at major conferences like ESMO and WCLC, particularly those with promising clinical data [17]. Group 3: Mining and Metals Performance - Luoyang Molybdenum's net profit for H1 2025 increased by 60% to CNY 8.67 billion, driven by rising copper and cobalt prices alongside increased production [18][19]. - Zijin Mining reported a 54.41% year-on-year increase in net profit for H1 2025, attributed to a significant rise in gold production and prices [22][23]. - Cloud Aluminum's net profit for H1 2025 grew by 10%, with a strong performance in aluminum production and a proposed cash dividend of CNY 3.2 per share [20][21]. Group 4: Real Estate and Property Management - Poly Property's revenue for H1 2025 reached CNY 8.4 billion, with a net profit increase of 5%, indicating steady growth in property management services [31][32]. - Greentown China reported a significant decline in net profit by 89.7% for H1 2025, primarily due to uneven revenue recognition and asset impairment provisions [33][34]. - The company maintained a strong sales performance, with total sales area down only 10% compared to the industry average, reflecting resilience in a challenging market [34].

Group 1 - The core viewpoint is that Smoore International (06969) has experienced a significant decline in net profit for the first half of the year, primarily due to increased R&D expenses and other costs, leading to a drop in stock price [1][2] - For the first half of the year, Smoore International reported revenue of 6.013 billion RMB, an increase of 18.3% year-on-year, while adjusted net profit was 737 million RMB, a decrease of 2.1%, and net profit was 492 million RMB, down 27.96% [1] - The company declared an interim dividend of 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Group 2 - UBS reported that the decline in net profit was largely due to increased stock-based compensation, rising sales and development expenses, and a higher tax rate [2] - Management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe, although short-term profitability will still be impacted by R&D expenses [2] - UBS has lowered its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, reflecting higher sales, marketing, and R&D expenditures, and has reduced the target price from 14 HKD to 13.11 HKD while maintaining a "sell" rating [2]

Core Viewpoint - Smoore International (06969) experienced a significant decline in stock price following its interim results, with a drop of over 6% in early trading and a current price of 19.23 HKD, despite a revenue increase of 18.3% year-on-year [1] Financial Performance - The company reported a revenue of 6.013 billion RMB for the first half of the year, reflecting an 18.3% increase year-on-year [1] - Adjusted net profit for the period was 737 million RMB, a decrease of 2.1% year-on-year [1] - The overall profit for the period was 492 million RMB, down 27.96% year-on-year [1] - The interim dividend declared was 0.20 HKD per share, compared to 0.05 HKD per share in the same period last year [1] Analyst Insights - Bank of America noted that Smoore's performance was generally in line with expectations, predicting a slight improvement in annual revenue growth, but continued pressure on profit margins [1] - UBS reported that the decline in net profit was primarily due to increased stock-based compensation, higher sales and development expenses, and a rising tax rate [1] - Management expressed optimism for continued revenue growth in the second half, supported by favorable policies for e-cigarettes in the US and Europe, although short-term profitability will be impacted by increased R&D spending [1] - The company is preparing to launch its own products in the US, with specific financial results from new business segments expected to be reflected by 2027 [1] - UBS downgraded its earnings forecast for the company from 10% to 33% for the years 2023 to 2027, citing higher sales, marketing, and R&D expenses, and lowered the target price from 14 HKD to 13.11 HKD, maintaining a "sell" rating [1]

Investment Rating - The investment rating for the company is "Outperform the Market" [7] Core Views - The company's revenue for the first half of 2025 reached 6.013 billion HKD, representing a year-on-year increase of 18.3%, while adjusted profit slightly decreased by 2.1% to 737 million HKD [1] - The company is benefiting from the global trend towards regulatory compliance, with its vaping business recovering as expected [1] - The company plans to distribute an interim dividend of 0.20 HKD per share [1] Revenue and Profit Analysis - The company's To B business revenue increased by 19.5% year-on-year to 4.74 billion HKD, with European revenue growing by 38.0% to 2.73 billion HKD [2] - In the U.S., revenue was 1.5% higher at 1.89 billion HKD, while domestic revenue decreased by 6.1% to 120 million HKD [2] - The self-owned brand business revenue grew by 14.1% year-on-year to 1.27 billion HKD, with European revenue increasing by 15.1% [3] Long-term Growth Potential - The successful commercialization of HNB products and steady progress in vaping medical applications are expected to drive long-term growth [3] - The company launched high-end HNB products in Japan, with plans for nationwide expansion and entry into more key markets in the second half of 2025 [3] Financial Forecasts - The profit forecast for 2025-2027 has been adjusted, with expected net profits of 1.239 billion HKD, 1.822 billion HKD, and 2.565 billion HKD respectively, reflecting year-on-year changes of -4.9%, +47.0%, and +40.8% [4] - The diluted EPS is projected to be 0.20, 0.29, and 0.41 HKD for 2025, 2026, and 2027 respectively, with corresponding P/E ratios of 98, 67, and 48 [4]

Core Viewpoint - The company's 1H25 performance aligns with expectations, showing revenue growth but a decline in net profit, indicating a mixed financial outlook amid evolving market conditions [1][2]. Financial Performance - Revenue for 1H25 reached 6.01 billion, an 18.3% year-on-year increase, while net profit attributable to shareholders was 500 million, a 30.8% decline. Adjusted net profit after stock incentive expenses was 740 million, down 2.1% [1]. - The company declared an interim dividend of 0.2 HKD per share, with a payout ratio of 225.1%, significantly higher than the 38.7% in 1H24, indicating increased shareholder returns [1]. Market Trends - The ToB revenue grew by 19.5% to 4.739 billion, driven by strong performance in Europe and potential improvements in the U.S. market due to stricter regulations [1]. - In Europe, revenue surged by 38% to 2.73 billion, benefiting from regulatory changes that favored compliant companies [1]. - U.S. revenue increased by 1.5% to 1.89 billion, with expectations of continued improvement as enforcement tightens [1]. - Domestic revenue, however, saw a decline of 6.1% to 120 million [1]. Product Development - The ToC revenue rose by 14.1% to 1.274 billion, with significant growth in the APV segment, particularly in Europe, where new product launches are driving user conversion [2]. - The APV revenue in Europe and the U.S. was 1.07 billion and 170 million, respectively, with declines of 15.1% and 6.7% [2]. - The nebulization beauty segment experienced a remarkable growth of 2595% to 30.618 million, with over 10,000 C-end users and more than 100 B-end partnerships established [2]. Profitability and Costs - The overall gross margin remained stable, decreasing slightly by 0.5 percentage points to 37.3%. However, the net profit margin fell by 5.9 percentage points to 8.3%, and adjusted for stock incentive expenses, it decreased by 1.2 percentage points to 12.3% [2]. - Sales expense ratio increased by 0.8 percentage points to 8.2% due to heightened investment in self-owned brands, while R&D expense ratio decreased by 2.9 percentage points to 12% [2]. - Management expenses rose significantly by 15.5 percentage points to 22.2%, primarily due to increased stock incentive costs [2]. Growth Outlook - The HNB segment is expected to accelerate globally, with Glo Hilo's market share in Japan increasing by 1.5% during its sales period, indicating strong growth potential [3]. - The regulatory environment for vaping products in Europe and the U.S. is expected to lead to a more standardized industry, allowing the company to recover market share and continue growing [3]. - The company is also focusing on developing nebulization medical products and expanding its nebulization beauty segment domestically, which opens up additional growth opportunities [3]. Profit Forecast and Valuation - The company maintains its profit forecast and industry outperform rating, with a target price reflecting a 4% upside from the current stock price [3].

Core Viewpoint - UBS has downgraded the target price for Smoore International (06969) to HKD 13.11 and maintained a "Sell" rating due to a decline in mid-term net profit primarily driven by increased equity compensation, rising sales and development expenses, and a higher tax rate [1] Financial Performance - Smoore International's mid-term net profit has decreased, largely attributed to increased equity compensation and higher sales and development expenditures [1] - The company's management remains optimistic about revenue growth in the second half of the year, citing favorable policies for e-cigarettes in the US and Europe [1] Future Outlook - Short-term profitability is expected to be impacted by increased R&D spending as the company prepares to launch its own products in the US [1] - More specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products are anticipated to be reflected by 2027 [1] Earnings Forecast - UBS has revised its earnings forecast for Smoore International for the years 2023 to 2027 down by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1]

Core Viewpoint - UBS report indicates that Smoore International's mid-term net profit has declined primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management is optimistic about continued revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by increased R&D expenses as it prepares to launch its own products in the US [1] Future Outlook - Management expects more specific financial results from new business segments such as heated tobacco, inhalation therapy, and beauty aerosol products to be reflected by 2027 [1] - UBS has lowered its earnings forecast for the company from this year to 2027 by 10% to 33%, reflecting higher sales, marketing, and R&D expenses [1] Target Price and Rating - The target price has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]

Core Viewpoint - UBS report indicates that Smoore International (06969) experienced a decline in mid-term net profit primarily due to increased equity compensation, rising sales and development expenses, and higher tax rates [1] Financial Performance - The management remains optimistic about revenue growth in the second half of the year, supported by favorable e-cigarette policies in the US and Europe [1] - The company’s short-term profitability is still impacted by higher R&D expenditures as it prepares to launch its own products in the US [1] Future Outlook - More specific financial results from new business segments such as heated tobacco, inhalation therapies, and beauty aerosol products are expected to be reflected by 2027 [1] - UBS has revised its earnings forecast for the company downwards by 10% to 33% for the years 2023 to 2027, reflecting increased sales, marketing, and R&D expenses [1] Target Price Adjustment - The target price for Smoore International has been reduced from HKD 14 to HKD 13.11, while maintaining a "Sell" rating [1]

Investment Rating - The investment rating for the company is "Buy" and is maintained [9] Core Views - The company achieved a revenue of 6.013 billion HKD in H1 2025, representing an 18% year-on-year increase. However, net profit was 492 million HKD, down 28% year-on-year, while adjusted net profit was 737 million HKD, a decrease of 2% year-on-year. The company also reported a share-based payment expense of 245 million HKD for H1 2025 and declared an interim dividend of 0.2 HKD per share, totaling approximately 1.24 billion HKD in dividends to shareholders [2][6] Revenue Analysis - The revenue growth in H1 2025 was primarily driven by the recovery of the vaping business. Specifically, the TOB (business-to-business) segment saw a 19% year-on-year increase, accounting for 79% of total revenue. Revenue from the TOB segment in the US, mainland China, Europe, and other regions showed varied performance, with increases of 1%, decreases of 6%, and increases of 38% respectively. The TOC (business-to-consumer) segment also grew by 14%, making up 21% of total revenue, with significant growth in mainland China at 2595% year-on-year [10] Profitability Analysis - The overall performance met the central expectations of the earnings forecast, with adjusted profits down 2% year-on-year. The decline in net profit was attributed to insufficient revenue and gross profit growth to offset rising expenses, including a significant increase in share-based payment expenses due to a stock incentive plan launched in late 2024. Additionally, distribution and sales expenses rose by 31% to 491 million HKD, and professional fees related to legal and compliance services surged by 820% to 140 million HKD [10] HNB Business Development - A significant milestone for the company in H1 2025 was the launch of Glo Hilo in collaboration with British American Tobacco. The product received positive consumer feedback during trials in Serbia and Sendai, Japan, with highlights including a close-to-tobacco flavor and reduced preheating time. The company plans to expand Glo Hilo across Japan in September 2025 and into more key markets later in the year. The company aims to continue investing in R&D for HNB products to maintain technological leadership and enhance customer adoption rates [10] Growth Potential - The company is optimistic about its growth potential in the global new tobacco trend. The vaping segment is showing signs of recovery, benefiting from regulatory shifts and increased market share among major clients. The HNB business has significant growth potential, especially considering the current market share of IQOS at over 70%. The industry is expected to continue growing at a double-digit annual rate, with ample room for penetration as the current global penetration rate is only about 6%. Long-term growth trends are also positive for medical vaping and special-purpose vaping [10]